# A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

> **NCT06952530** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 487 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06952530
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 487 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952530, "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06952530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*